Corona Remedies IPO: Full Details, Dates, Financials, Strengths, Risks & Complete Review
The Corona Remedies IPO is one of the most talked-about pharmaceutical IPOs of the year, thanks to its strong financial growth, diversified product portfolio, and increasing market presence in India’s chronic and acute therapy segments. If you are a retail investor looking for a complete, easy-to-understand, SEO-friendly analysis, this article covers everything you need to know.
✅ Corona Remedies IPO – Important Dates
| Event | Date |
|---|---|
| IPO Bidding Opens | 08 Dec 2025 |
| IPO Bidding Closes | 10 Dec 2025 |
| Allotment Date (Tentative) | 11 Dec 2025 |
| Refunds / Allotment Finalization | 12 Dec 2025 |
| Shares Credit to Demat | 15 Dec 2025 |
| Listing Date (Tentative) | 16 Dec 2025 |
💰 Corona Remedies IPO Price, Lot Size & Investment Details
| Detail | Information |
|---|---|
| Price Band | ₹1,008 – ₹1,062 |
| Market Lot | 14 shares |
| Minimum Investment | ₹14,112 (for 1 lot) |
| Issue Size | ₹655.87 Cr |
| Retail Investor Type | Regular / Employee / HNI |
🌐 About Corona Remedies Limited
Corona Remedies Limited is an India-focused pharmaceutical formulations company specializing in:
-
Women’s healthcare
-
Diabetes management
-
Cardiovascular care
-
Dermatology
-
Chronic + sub-chronic therapies
Founded: 2004
MD/CEO: Mr. Nitin Kumar Krishnakumar Mehta
Parent Organization: Corona Remedies Ltd
The company has built a strong presence in branded generics, with continuous expansion in both urban and semi-urban markets. It has also been among the fastest-growing branded pharma companies in India.
📊 Financial Performance of Corona Remedies
Based on the provided charts:
1️⃣ Revenue Growth
-
FY23: ₹888.60 Cr
-
FY24: ₹1,068.74 Cr
-
FY25: ₹1,184.02 Cr
➡️ Strong and consistent growth in top-line revenue over the past 3 years.
2️⃣ Profit After Tax (PAT)
-
FY23: ₹84.83 Cr
-
FY24: ₹93.50 Cr
-
FY25: ₹104.64 Cr
➡️ Indicates steady profitability and improving margins.
3️⃣ Total Assets
-
FY23: ₹654.60 Cr
-
FY24: ₹742.98 Cr
-
FY25: ₹816.11 Cr
➡️ Shows the company’s expanding scale and capital strength.
⭐ Strengths of Corona Remedies
From the screenshots, these are the major strengths:
1. Strong Growth Among Top 30 Pharmaceutical Companies
-
CAGR of 16.17% between FY22 and FY25.
-
Revenue and prescription growth consistently above market average.
2. Focus on High-Growth Therapeutic Areas
-
Women’s healthcare
-
Cardio-diabetes
-
Chronic therapies
-
Dermatology
These segments show consistent demand in India.
3. Strong Product Launch Pipeline
-
High share of new product launches in domestic sales.
-
Covers 14.43% of India’s market for new products.
4. Diversified Product Portfolio
-
71 brands contributing across major therapy areas.
-
Reduces dependency risk from a single drug category.
5. Strong Prescription Growth
-
Fastest-growing in IPM between MAT 2022–2025.
-
7.51% contribution from specialists and super-specialists.
6. Proven Profitability
-
Sustained improvement in EBITDA and PAT.
-
Robust financial discipline and cost control.
⚠️ Risks Associated with Corona Remedies
The screenshots highlight several key risks:
1. High Dependence on Limited Therapy Segments
-
A large portion of revenue comes from women’s health and cardiology.
2. Geographic Concentration Risk
-
Major domestic sales come from states like Gujarat, Maharashtra, MP, and UP.
-
Any slowdown there can affect growth.
3. Reliance on Third-Party Distributors
-
Problems in distribution networks can impact sales.
4. Manufacturing Concentration
-
Manufacturing facilities in Sikkim and Himachal Pradesh handle majority of production.
-
Political/regulatory changes may affect operations.
5. High Competition
-
Competes with large pharma players in generics and branded prescription markets.
6. Regulatory & Compliance Risks
-
Pharma companies must meet strict quality standards.
-
Any non-compliance can result in penalties or operational disruption.
7. Inventory & Supply Chain Risks
-
Dependency on raw materials and timely distribution.
🧾 Application Details of Corona Remedies IPO
| Category | Price Band | Maximum Amount | Lot Size |
|---|---|---|---|
| Retail (Regular) | ₹1,008 – 1,062 | Up to ₹2 Lakh | 14 |
| Employee | ₹1,044 – 1,108 | Up to ₹2 Lakh | 14 |
| HNI / NII | ₹1,008 – 1,062 | ₹2 – 5 Lakh+ | 14 |
❓ Top Corona Remedies IPO FAQs
What is the issue size of Corona Remedies IPO?
The total issue size is ₹655.87 crore.
What is pre-apply for Corona Remedies IPO?
It allows you to apply 4 days before IPO bidding opens.
When will IPO allotment be announced?
Tentatively on 11 December 2025.
When will shares be listed?
Listing date is 16 December 2025 (tentative).
Where will the shares be listed?
On BSE and NSE.
Who is the registrar?
BIGSHARE Services Pvt Ltd
📝 Conclusion – Should You Consider Corona Remedies IPO?
Corona Remedies IPO shows strong financial performance, consistent revenue and profit growth, and a solid portfolio in high-demand therapy categories. The company has shown:
-
Strong CAGR growth
-
High prescription market share
-
Brand stability
-
Expanding operations
However, investors must consider risks like geographic concentration, industry competition, and regulatory dependency before applying.
Verdict:
✔ Suitable for investors looking for exposure to the pharmaceutical & formulations sector
✔ Strong fundamentals + stable growth
✔ Good long-term potential
But always evaluate risk appetite before investment.
⚠️ Disclaimer
This article is NOT financial advice.
It is created only for educational and informational purposes based on the data visible in the screenshots provided by the user.
Please consult your financial advisor before making any investment decisions.
tags : Corona Remedies IPO, ipo price,ipo date,Ipo listing,IPO Lot SIze,About IPO, All about IPO , About Company ,Investment,
Comments
Post a Comment